Diagnosis and treatment of endometriosis and related conditions

Patent metadata

Field	Value
Publication number	US-9651561-B2
Application number	US-201314443804-A
Country	US
Kind code	B2
Filing date	Nov 13, 2013
Priority date	Nov 20, 2012
Publication date	May 16, 2017
Grant date	May 16, 2017

Abstract

The technology described herein relates to KIM-1 and the diagnosis, prognosis, and treatment of endometrial diseases and disorders.

First claim

What is claimed herein is:

1. A method of administering a treatment for a condition selected from the group consisting of:
endometriosis; endometriotic cysts; or endometrioid cancer;
to a subject, the method comprising
administering the treatment for the condition to a subject determined to have a level of kidney injury molecule 1 (KIM-1) in a urine test sample obtained from the subject which is greater than 500 pg of KIM-1 polypeptide per mg of urinary creatinine.

2. The method of claim 1 , the method further comprising a step of determining that the subject has normal kidney function.

3. The method of claim 2 , wherein the step of determining that the subject has normal kidney function comprises a kidney function urinalysis or kidney function blood test.

4. The method of claim 1 , wherein the treatment is selected from the group consisting of:
a hormonal treatment; progesterone; progestin; an oral contraceptive; a hormonal contraceptive; danocrine; gentrinone; a gonadotrophin releasing hormone agonist; Lupron; danazol; an aromatase inhibitor; pentoxifylline; surgical treatment; laparoscopy; cauterization; and cystectomy.

5. The method of claim 1 , wherein the level of KIM-1 is determined by measuring the level of KIM-1 polypeptide.

6. The method of claim 5 , wherein the KIM-1 polypeptide comprises the ectodomain of KIM-1 polypeptide.

7. The method of claim 1 , wherein the endometriosis has or is at risk of progressing to a condition selected from the group consisting of:
endometriotic cyst; ovarian carcinoma; and clear cell ovarian cancer.

Assignees

• Brigham & Womens Hospital Inc
• The Brigham And Womens'S Hospital Inc

Inventors

• Bonventre Joseph V
• Sabbisetti Venkata

Classifications

• A61P7/04

  Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents · CPC title

• G01N33/689 Primary

  related to pregnancy or the gonads · CPC title

• A61K38/00

  Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title

• A61P15/00

  Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives · CPC title

• A61K38/09

  Luteinising hormone-releasing hormone [LHRH] {, i.e. Gonadotropin-releasing hormone [GnRH]}; Related peptides · CPC title